Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis
Sponsor: ACADIA Pharmaceuticals Inc.
Listed as NCT03325556, this PHASE3 trial focuses on Dementia-related Psychosis and remains completed. Sponsored by ACADIA Pharmaceuticals Inc., it has been updated 24 times since 2017, reflecting substantial change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
24 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE3
▶ Show 19 earlier versions
-
May 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Dec 2019 — May 2020 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Nov 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2019 — Nov 2019 [monthly]
Recruiting PHASE3
-
Aug 2019 — Sep 2019 [monthly]
Recruiting PHASE3
-
Jun 2019 — Aug 2019 [monthly]
Recruiting PHASE3
-
May 2019 — Jun 2019 [monthly]
Recruiting PHASE3
-
Mar 2019 — May 2019 [monthly]
Recruiting PHASE3
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE3
-
Dec 2018 — Feb 2019 [monthly]
Recruiting PHASE3
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE3
-
Oct 2018 — Nov 2018 [monthly]
Recruiting PHASE3
-
Aug 2018 — Oct 2018 [monthly]
Recruiting PHASE3
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE3
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Mar 2018 — May 2018 [monthly]
Recruiting PHASE3
-
Dec 2017 — Mar 2018 [monthly]
Recruiting PHASE3
-
Nov 2017 — Dec 2017 [monthly]
Recruiting PHASE3
First recorded
Sep 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ACADIA Pharmaceuticals Inc.
For direct contact, visit the study record on ClinicalTrials.gov .